Please select the outcome measures that correspond to the clinical trial below.
Title: Treatment of Functional Impairment in Patients With Heart Failure and Comorbid Depression
Brief Summary: The purpose of the study is to test whether Cognitive Behavior Therapy (CBT) plus heart failure self-care education is superior to "usual care" for depression.


Options:
A: Recruitment Feasibility: Percent of Participants Screened Eligible (6 months); Recruitment Feasibility: Percent of Participants Enrolled (6 months); MBCT Feasibility: Percent of Participants Retained (6 months); Mindfulness Based Cognitive Therapy (MBCT) Feasibility: Percent of Participants Adherent to Treatment (6 months); Mindfulness Based Cognitive Therapy (MBCT) Feasibility: Percent of Participants Adherent to Home Practice (6 months); Control Group Feasibility: Percent of Participants Retained (6 months); Control Group Feasibility: Percent of Participants Adherent to Treatment (6 months); Control Group Feasibility: Percent of Participants Adherent to Home Practice (6 months); Videoconferencing Feasibility: Number of Sessions Missed Due to Technical Problems (6 months); Blood Spot Feasibility: Percent of Blood Spot Samples Submitted at Baseline (At Baseline (Month 0)); Blood Spot Feasibility: Percent of Blood Spot Samples Submitted at Post-intervention (At Post Intervention (Month 3)); Mindfulness Based Cognitive Therapy (MBCT) Acceptability: Ratings of Intervention Satisfaction (At post intervention (Month 3)); Mindfulness Based Cognitive Therapy (MBCT) Acceptability: Percent of Participants Who Plan to Continue Using the Skills (6 months); Mindfulness Based Cognitive Therapy (MBCT) Acceptability: Percent of Participants Who Would Recommend the Program (6 months); Control Group Acceptability: Ratings of Intervention Satisfaction (6 months); Control Group Acceptability: Percent of Participants Who Plan to Continue Using the Skills (6 months); Control Group Acceptability: Percent of Participants Who Would Recommend the Program (6 months); Videoconferencing Acceptability: Ratings of Videoconferencing Satisfaction (6 months); Blood Spot Acceptability: Blood Spot Collection Ease (6 months); Blood Spot Acceptability: Blood Spot Collection Comfort (6 months)
B: BDI-II score at 6 months (Baseline, 3 months, 6 months, 9 months , 12 months)
C: Score of Seattle Angina Questionnaire（SAQ ） (at the 0-week); Score of Seattle Angina Questionnaire（SAQ ） (at the 4-week); Score of Seattle Angina Questionnaire（SAQ ） (at the 8-week); Score of Seattle Angina Questionnaire（SAQ ） (at the 12-week); Frequency of angina pectoris related symptoms every week (at the 0-week); Frequency of angina pectoris related symptoms every week (at the 1-week); Frequency of angina pectoris related symptoms every week (at the 2-week); Frequency of angina pectoris related symptoms every week (at the 3-week); Frequency of angina pectoris related symptoms every week (at the 4-week); Frequency of angina pectoris related symptoms every week (at the 5-week); Frequency of angina pectoris related symptoms every week (at the 6-week); Frequency of angina pectoris related symptoms every week (at the 7-week); Frequency of angina pectoris related symptoms every week (at the 8-week); Frequency of angina pectoris related symptoms every week (at the 9-week); Frequency of angina pectoris related symptoms every week (at the 10-week); Frequency of angina pectoris related symptoms every week (at the 11-week); Frequency of angina pectoris related symptoms every week (at the 12-week)
D: Change in Hospital Anxiety and Depression Scale (HADS) (Baseline pre treatment, four-month post baseline)

Answer: B